Soleno Therapeutics Inc (NASDAQ: SLNO) kicked off on Friday, up 3.56% from the previous trading day, before settling in for the closing price of $53.03. Over the past 52 weeks, SLNO has traded in a range of $21.30-$56.81.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -1.94%. With a float of $27.68 million, this company’s outstanding shares have now reached $31.68 million.
In an organization with 42 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 41.09%, operating margin of -1982.56%, and the pretax margin is -1898.11%.
Soleno Therapeutics Inc (SLNO) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Soleno Therapeutics Inc is 28.78%, while institutional ownership is 78.69%. The most recent insider transaction that took place on Oct 21 ’24, was worth 51,416,038. Before that another transaction happened on Oct 07 ’24, when Company’s Rule 144 Affiliate proposed sale 2,522,751 for $49.63, making the entire transaction worth $125,204,132.
Soleno Therapeutics Inc (SLNO) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.95 earnings per share (EPS), lower than consensus estimate (set at -0.58) by -0.37. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.64 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.94% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to 24.34% growth over the previous five years of trading.
Soleno Therapeutics Inc (NASDAQ: SLNO) Trading Performance Indicators
Take a look at Soleno Therapeutics Inc’s (SLNO) current performance indicators. Last quarter, stock had a quick ratio of 29.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.43, a number that is poised to hit -0.60 in the next quarter and is forecasted to reach -2.03 in one year’s time.
Technical Analysis of Soleno Therapeutics Inc (SLNO)
Let’s dig in a bit further. During the last 5-days, its volume was 0.53 million. That was better than the volume of 0.46 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 48.56%. Additionally, its Average True Range was 2.31.
During the past 100 days, Soleno Therapeutics Inc’s (SLNO) raw stochastic average was set at 90.49%, which indicates a significant increase from 74.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.79% in the past 14 days, which was lower than the 56.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $50.54, while its 200-day Moving Average is $46.07. However, in the short run, Soleno Therapeutics Inc’s stock first resistance to watch stands at $56.15. Second resistance stands at $57.37. The third major resistance level sits at $58.68. If the price goes on to break the first support level at $53.62, it is likely to go to the next support level at $52.31. Assuming the price breaks the second support level, the third support level stands at $51.09.
Soleno Therapeutics Inc (NASDAQ: SLNO) Key Stats
The company with the Market Capitalisation of 2.13 billion has total of 33,411K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -38,990 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -21,850 K.
